Lcnb Corp Sells 2,146 Shares of Novartis AG (NYSE:NVS)
Lcnb Corp lessened its holdings in shares of Novartis AG (NYSE:NVS) by 14.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,617 shares of the company’s stock after selling 2,146 shares during the quarter. Lcnb Corp’s holdings in Novartis were worth $1,152,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. Capital Advisors Ltd. LLC grew its stake in shares of Novartis by 119.0% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,084 shares of the company’s stock worth $99,000 after acquiring an additional 589 shares in the last quarter. Crawford Investment Counsel Inc. grew its stake in shares of Novartis by 8.9% in the 1st quarter. Crawford Investment Counsel Inc. now owns 2,581 shares of the company’s stock worth $248,000 after acquiring an additional 212 shares in the last quarter. Penbrook Management LLC grew its stake in shares of Novartis by 18.2% in the 2nd quarter. Penbrook Management LLC now owns 6,500 shares of the company’s stock worth $594,000 after acquiring an additional 1,000 shares in the last quarter. Private Trust Co. NA grew its stake in shares of Novartis by 9.1% in the 2nd quarter. Private Trust Co. NA now owns 3,496 shares of the company’s stock worth $319,000 after acquiring an additional 293 shares in the last quarter. Finally, Burns J W & Co. Inc. NY grew its stake in shares of Novartis by 1.3% in the 2nd quarter. Burns J W & Co. Inc. NY now owns 15,731 shares of the company’s stock worth $1,436,000 after acquiring an additional 200 shares in the last quarter. Institutional investors and hedge funds own 11.87% of the company’s stock.
Several analysts have recently issued reports on the stock. Kepler Capital Markets lowered shares of Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Zacks Investment Research downgraded shares of Novartis from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a report on Friday, July 19th. Guggenheim raised shares of Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price target on the stock in a report on Wednesday, April 24th. Liberum Capital raised shares of Novartis from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Finally, Argus boosted their price target on shares of Novartis to $105.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. They noted that the move was a valuation call. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Novartis currently has a consensus rating of “Hold” and a consensus target price of $90.63.
Novartis (NYSE:NVS) last released its quarterly earnings data on Thursday, July 18th. The company reported $1.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.20 by $0.14. The business had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $11.45 billion. Novartis had a net margin of 23.27% and a return on equity of 18.55%. The company’s revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.29 earnings per share. On average, equities research analysts forecast that Novartis AG will post 5.06 earnings per share for the current fiscal year.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
See Also: Buyback For Investors Defined
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.